Day 3 of Fall Clinical 2026 featured roflumilast data in genital psoriasis, long-term JAK inhibitor safety in atopic dermatitis, and expert insights on setting expectations in HS, treating advanced cSCC, and screening aesthetic patients.
Quiz|Articles|April 5, 2026
Dermatology Times Spot Test: April 5, 2026
Author(s)Marie Bosslett, Assistant Editor
Listen
0:00 / 0:00
Key Takeaways
- Weekly Spot Test questions are positioned as a recurring tool to assess knowledge across core dermatology themes and fast-moving developments.
- This week’s focus centers on insights generated at the AAD Annual Meeting in Denver, leveraging conference momentum and topical relevance.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Advertisement
Welcome to Dermatology Times' Spot Test.
Each week, dive into a series of thought-provoking questions designed to test your understanding of essential topics, trends, and breakthroughs in dermatology. We’re reflecting on a fantastic week in Denver spent at the
Do you have a set of quiz questions to share? Contact editor Marie Bosslett at
According to Reid Waldman, MD, co-founder and CEO of Veradermics, what is a key theoretical advantage of extended-release minoxidil at the hair follicle level?
Chinweike Ukomadu, MD, PhD, therapeutic area head for GI and inflammation at Takeda Pharmaceuticals, outlined phase 3 trials, comparing zasocitinib with placebo and which active comparator?
Which anatomical area showed notable treatment success in the phase 2 INTEGUMENT-INFANT study of roflumilast, according to dermatologist and chief medical officer of Aructis Biotherapeutics, Patrick Burnett, MD, PhD?
Advertisement
Related to this article
In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.
Patients with plaque psoriasis treated with roflumilast cream or foam reported greater improvements in sexual function and relationships vs vehicle, including those with genital involvement at baseline.
The second day of Fall Clinical 2026 brought new psoriasis data on ixekizumab plus tirzepatide and 2-year icotrokinra results, along with 3-year nemolizumab findings, upadacitinib switch data, and expert guidance on choosing a biologic in atopic dermatitis.
No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.
Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
At week 112, at least 72% of patients on icotrokinra held PASI 90 and at least 44% held PASI 100, with no new safety signals reported.
Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
JAK Inhibitor Safety in Atopic Dermatitis: Long-Term Epidemiology Data
2
Roflumilast Eases Sexual Difficulties in Psoriasis With Genital Involvement
3
No Observed Skin Lesion Flares After Switching to Upadacitinib in Atopic Dermatitis
4
Managing Treatment Expectations in Hidradenitis Suppurativa: What to Tell Patients Before Starting Therapy
5